Drug Profile
Research programme: pain therapeutics - Essen BioScience/Nycomed
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Essen BioScience; Nycomed
- Developer Essen BioScience; Takeda Pharmaceuticals International GmbH
- Class Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pain in Switzerland
- 30 Sep 2011 Nycomed has been acquired by Takeda
- 22 Jun 2010 Early research in Pain in Switzerland (unspecified route)